Ranbaxy, Teva settle New York '1st-to-file pact' antitrust claims
This article was originally published in Scrip
Executive Summary
Ranbaxy and Teva will each pay $150,000 to settle charges brought by New York the generic drug makers violated antitrust laws by entering into a December 2010 pact not to challenge each other's claim of sole first-to-file exclusivity filed with the FDA for generic versions of Pfizer's cholesterol-lowering drug Lipitor (atorvastatin) and other drugs.